Oral Micronized Progesterone Microdosing Protocols: What the Evidence Actually Shows

What oral micronized progesterone is, and why the dose question is not simple

Oral micronized progesterone (OMP) is a bioidentical progestogen, chemically identical to endogenous human progesterone, formulated as a micronized powder suspended in peanut oil inside a capsule. In the United States it is sold under the brand name Prometrium in 100 mg and 200 mg strengths. It differs pharmacologically from synthetic progestins such as medroxyprogesterone acetate (MPA) or levonorgestrel, which do not convert to the same neuroactive metabolites and bind the progesterone receptor with different affinity and duration.

The dosing question matters because OMP does two separate jobs through two separate pathways, and those pathways do not share a dose-response curve. Progesterone-receptor binding in the endometrium suppresses estrogen-driven proliferation and is the basis for endometrial protection. Separately, oral OMP undergoes substantial first-pass hepatic metabolism to allopregnanolone, a neurosteroid that modulates GABA-A receptors and produces the sedative and anxiolytic effects some women notice. A dose that feels adequate for sleep is not automatically an adequate endometrial-protective dose, and the reverse is also true.

Oral micronized progesterone (Prometrium) is described in prescribing information as approved at 200 mg/day for 12 days per cycle for endometrial protection in postmenopausal women with a uterus using estrogen therapy; no dose below that labeled regimen, including the widely used off-label 100 mg/day continuous regimen and the lower "microdose" ranges discussed in some clinical settings, has been validated in an adequately powered randomized trial for endometrial-hyperplasia prevention. Clinicians who use lower doses are extrapolating from pharmacokinetic reasoning, smaller observational cohorts, and mechanistic plausibility rather than following a guideline-endorsed protocol, which is why individualized endometrial surveillance is the safety condition attached to any dose reduction.

The FDA label versus what is actually prescribed

The current FDA-approved labeling for Prometrium specifies 200 mg orally once daily at bedtime for 12 consecutive days per 28-day cycle, used together with conjugated estrogens, for opposing estrogen's effect on the endometrium in women who have not had a hysterectomy. This is the regimen tested in the trial base the FDA relied on for approval, most notably the Postmenopausal Estrogen/Progestin Interventions (PEPI) study from the 1990s, which compared cyclic OMP against MPA and against unopposed estrogen. That trial is well known in the menopause literature for showing endometrial protection with OMP broadly comparable to MPA, alongside a more favorable effect on HDL cholesterol than MPA produced. The exact hyperplasia rates and lipid deltas reported in that trial should be checked against the primary publication before being quoted as precise figures in patient materials; this draft intentionally avoids restating specific percentages that could not be re-verified against a confirmed source.

In practice, many prescribers now use continuous 100 mg/day OMP instead of cyclic 200 mg, largely to avoid the scheduled withdrawal bleeding that cyclic dosing produces. This is an off-label regimen relative to the FDA label's 12-day cyclic instructions. Continuous 100 mg/day has a supportive but smaller observational evidence base than the cyclic 200 mg regimen, and current UK menopause society guidance acknowledges continuous lower-dose regimens as a reasonable clinical option while noting that the endometrial-safety dataset for continuous dosing is smaller than for cyclic dosing (Hamoda et al., British Menopause Society, 2023 recommendations).

Is there real evidence for doses below 100 mg/day?

"Microdosing" in this context generally means doses in the 25 to 75 mg/day range, sometimes prescribed as compounded capsules or through telehealth platforms marketing individualized hormone protocols. The honest answer is that no adequately powered randomized trial has evaluated 50 mg/day, or lower, OMP against an endometrial-biopsy or hyperplasia endpoint in estrogen-primed postmenopausal women. What exists instead is indirect evidence:

• Pharmacokinetic studies of single-dose OMP show that serum progesterone concentration scales roughly with dose, so a 50 mg dose would be expected to produce meaningfully lower peak serum levels than 100 mg or 200 mg. Serum concentration is an imperfect surrogate for endometrial protection, because local tissue exposure and duration of receptor occupancy over 24 hours matter more than a single peak (Cmax) value.
• Small case series and cohort reports describe endometrial patterns in women using continuous OMP around 100 mg/day, generally reassuring, but these are observational, not randomized, and are not powered to detect an uncommon hyperplasia event.
• No published endometrial-outcome data specifically address continuous 50 mg/day OMP in estrogen-primed postmenopausal women. Extrapolating "half the dose, half the risk of inadequate protection" is a plausible pharmacological assumption, not an established clinical finding.

This is the central evidence gap of the "microdosing" conversation. It is not that lower doses are known to be unsafe. It is that the dose-response relationship for endometrial protection has not been mapped below roughly 100 mg/day in controlled research, which means a prescriber choosing 50 mg/day is making an individualized judgment call that needs an explicit surveillance plan attached to it, not an assumption of safety by extrapolation.

The compounding variable

Because Prometrium is only manufactured in 100 mg and 200 mg capsules that are not designed to be split reliably (the active ingredient is suspended in oil rather than present as a scored tablet), any prescription for doses below 100 mg currently requires a compounded product. Compounded drugs are not FDA-approved and are not subject to the same batch-consistency testing as an approved product. The FDA's general guidance on compounding explains that compounded medications can differ from the prescribed strength because they are not evaluated for safety, effectiveness, or quality the way an approved drug is (fda.gov, Compounding and FDA Questions and Answers). Anyone prescribing or using a compounded low-dose progesterone product should treat labeled strength as approximate rather than guaranteed, and this uncertainty should factor into the endometrial-surveillance decision, since a "50 mg" capsule could plausibly be delivering more or less than that amount.

Where the sleep and mood benefits come from, and at what dose they appear

Oral progesterone's sedative and anxiolytic reputation is a metabolite effect, not a direct progesterone-receptor effect. After oral dosing, hepatic first-pass metabolism converts a substantial fraction of the dose to allopregnanolone and related neurosteroids, which positively modulate GABA-A receptors, the same receptor complex targeted by benzodiazepines. This is why oral dosing (rather than vaginal or transdermal, which largely bypass first-pass hepatic metabolism) is the pharmacologically rational choice when the goal is a sedative or anxiolytic effect, and why bedtime dosing is standard advice: peak allopregnanolone activity roughly coincides with the sedative trough a few hours after dosing.

Sleep benefits have been reported in the literature at doses in the 100 mg to 300 mg/night range, drawn from a mix of small crossover trials and open-label reports; the exact study designs, sample sizes, and effect sizes attached to the specific PubMed identifiers in earlier drafts of this material could not be independently confirmed and should be re-verified against the primary literature before being cited with precise numbers in a patient-facing document. No published randomized trial specifically isolates a 50 mg/night dose for sleep outcomes. Anecdotally and mechanistically, lower doses would be expected to produce a smaller allopregnanolone peak and a correspondingly smaller sedative effect, but the minimum effective dose for sleep has not been formally established.

The non-negotiable part: endometrial protection cannot be minimized casually

Unopposed estrogen therapy in a woman with a uterus increases endometrial cancer risk relative to no hormone therapy; this is one of the best-established findings in menopause medicine and is the entire reason progestogens are co-prescribed with systemic estrogen in women who have not had a hysterectomy. The minimum OMP dose that reliably prevents hyperplasia has been established for the labeled cyclic 200 mg regimen and is reasonably well supported for continuous 100 mg/day through observational data; it has not been established below that.

The Endocrine Society's menopause treatment guideline and general HRT prescribing guidance converge on the same principle even where they do not endorse a specific microdose number: any deviation from labeled or well-studied progestogen dosing in a woman with a uterus on estrogen therapy calls for individualized risk assessment and endometrial surveillance, typically transvaginal ultrasound and, where indicated, biopsy. Any unscheduled postmenopausal bleeding requires biopsy regardless of what dose of progestogen the patient is using; bleeding is never something to attribute to "just the low dose" without tissue evaluation.

Women who have had a hysterectomy do not need a progestogen for endometrial protection at all. In that population, low-dose oral progesterone prescribed purely for sleep or mood effects removes the endometrial-safety constraint from the dosing decision, and the calculus is genuinely different.

Evidence boundary: what is established, what is plausible, what is not established

Established: OMP 200 mg/day cyclic (12 days per 28-day cycle) is FDA-approved and has randomized trial support for endometrial protection in estrogen-treated postmenopausal women with a uterus. Oral dosing produces meaningfully higher allopregnanolone exposure than vaginal or transdermal routes, which is the mechanistic basis for oral progesterone's sedative reputation. Compounded medications are not FDA-approved and carry batch-to-batch potency uncertainty as a general regulatory matter.

Plausible but unproven: That continuous 100 mg/day provides endometrial protection reasonably close to the cyclic 200 mg regimen in most patients (supported by observational data, not a phase III RCT). That sleep and anxiolytic benefits persist meaningfully at 100 mg/night. That a proportionally lower serum progesterone level at 50 mg/day translates to proportionally lower, but still adequate, endometrial protection in every patient.

Not established: Any specific "microdose" (50 mg, 25 mg) as a validated endometrial-protective dose in women with a uterus on estrogen therapy. A minimum effective sleep dose below 100 mg/night. Any guideline-endorsed alternate-day or split-dose OMP protocol for endometrial protection.

A clinician-discussion and monitoring framework

This framework is intended as a structured basis for a conversation between a patient and prescriber considering an OMP dose below the labeled cyclic regimen. It is not a protocol to self-apply, and it does not replace individualized clinical judgment; a compounded low-dose product in particular should not be started without a documented surveillance plan.

Step 1: Establish the clinical goal before choosing a dose.

• Is the primary goal endometrial protection, sleep, mood, or a combination? The answer changes what "adequate" means and whether a uterus is even part of the decision.
• If the patient has had a hysterectomy, endometrial protection is not a consideration, and the dose can be chosen based on sleep/mood response and tolerability alone.

Step 2: Confirm what is being protected against, and by how much estrogen.

• Higher-dose systemic estrogen (for example, oral estradiol above 1 mg/day or a 0.1 mg/day patch) generally argues for staying at labeled or well-established off-label doses (200 mg cyclic or 100 mg continuous) rather than experimenting lower, because the progestogen needs to oppose a larger estrogenic stimulus.
• Low-dose topical estrogen with a documented thin baseline endometrial stripe is the scenario where a lower-dose conversation is most defensible, and even then it is a judgment call, not a validated protocol.

Step 3: Set a baseline before any dose reduction.

• Baseline transvaginal ultrasound with endometrial stripe measurement, documented before the first dose reduction.
• Documented rationale for choosing a below-label dose (sleep optimization, tolerability, explicit informed consent) in the chart.
• Explicit discussion that compounded products used for sub-100 mg dosing are not FDA-approved and may not deliver the exact labeled strength.

Step 4: Define a surveillance interval and stick to it.

• A follow-up transvaginal ultrasound, generally within 6 to 12 months of a dose change, is a reasonable floor; the exact interval should be set by the prescriber based on individual risk factors, not by this article.
• Any endometrial stripe finding that would normally prompt biopsy at a standard dose should prompt biopsy at a reduced dose. Lower progestogen dose is not a reason to raise the threshold for investigation.

Step 5: Define stop and escalation conditions explicitly, in advance.

• Any unscheduled or postmenopausal bleeding at any dose: stop assuming it is dose-related, and refer for biopsy before continuing or adjusting the regimen.
• Endometrial stripe thickening beyond the locally used threshold on surveillance ultrasound: escalate to biopsy regardless of symptom status.
• New or worsening pelvic pain, pressure, or discharge: evaluate independently of the progesterone dose question.
• Known peanut allergy: Prometrium capsules are contraindicated; a compounded alternative in a different vehicle would need separate evaluation.
• Concurrent use of strong CYP3A4 inducers (for example, rifampin, carbamazepine, phenytoin) or inhibitors (for example, certain azole antifungals): flag for dose or monitoring reconsideration, since these can meaningfully shift OMP serum levels in either direction.

Where label guidance ends and individualized care begins: the FDA label supports 200 mg/day cyclic. Continuous 100 mg/day is off-label but has a reasonable, though non-randomized, evidence base and appears in professional society guidance as an accepted clinical option. Anything below 100 mg/day in a woman with a uterus on estrogen therapy sits outside both the label and the current guideline evidence base; it is site- and clinician-level judgment that requires the surveillance structure above, informed consent documentation, and a low threshold for biopsy.

Practical prescribing notes

Oral micronized progesterone is metabolized primarily through CYP3A4, so strong inducers can lower effective exposure and strong inhibitors can raise it; either direction can matter for both endometrial protection and sedation. Taking OMP with food, particularly a higher-fat meal, increases absorption compared with a fasting state, which is one reason consistent bedtime administration with or without food, kept consistent from day to day, is generally recommended over an inconsistent pattern. Sedation is the most commonly reported side effect and is one reason bedtime dosing is preferred regardless of which dose is used. Anyone with a peanut allergy should not use Prometrium capsules specifically, given the peanut-oil vehicle; a compounded alternative in a different base would need to be discussed with the prescriber.

Frequently asked questions

References

2. U.S. Food and Drug Administration. Compounding and FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Reported figures for trials and cohort studies in this area, including those related to hormone therapy regimens, sleep and anxiolytic outcomes, and compounded hormone potency, vary between sources and have not been independently confirmed here. Readers should consult current guidelines and primary studies directly for precise figures.